Martin Dreyling, MD

Martin Dreyling, MD, speculated on the future role of BTK inhibitors either alone or in non-cytotoxic chemotherapy combinations for patients with MCL.

Martin Dreyling, MD, provides recommendations for use of acalabrutinib plus BR in pretreated MCL based on updated data from the phase 3 ECHO trial.

Martin Dreyling, MD, discusses prior findings and potential implications of the phase 3 ECHO trial of acalabrutinib plus BR in pretreated MCL.

Martin Dreyling, MD, discusses why adding acalabrutinib to bendamustine plus rituximab may benefit patients with pretreated, high-risk MCL.

Martin Dreyling, MD, PhD, discusses the use of BTK inhibitors in frontline mantle cell lymphoma.

Martin Dreyling, MD, PhD, discusses the efficacy of first-line acalabrutinib plus BR in high-risk patients with mantle cell lymphoma.

Martin Dreyling, MD, discusses the patient population studied in the TRIANGLE trial of ASCT plus ibrutinib-containing therapy in younger patients with MCL.

Martin Dreyling, MD, discusses the expanding role of BTK inhibitors in the treatment of mantle cell lymphoma.

Martin Dreyling, MD, discusses the rationale for evaluating the addtion of ibrutinib to chemoimmunotherapy and ASCT in mantle cell lymphoma.

Martin Dreyling, MD, discusses updated safety results from the randomized phase 3 TRIANGLE trial in younger patients with lower-risk MCL.

Martin Dreyling, MD, discusses ongoing trials exploring chemotherapy-free strategies in mantle cell lymphoma using BTK inhibitors.

Martin Dreyling, MD, discusses the role of autologous stem cell transplantation (ASCT) in the context of ibrutinib-containing first-line therapy for younger patients with MCL.

Martin Dreyling, MD, discusses the key safety data from the phase 3 TRIANGLE trial in younger patients with mantle cell lymphoma.

Martin Dreyling, MD, discusses key efficacy results from the phase 3 TRIANGLE study in mantle cell lymphoma.

Martin Dreyling, MD, associate professor, University of Munich, discusses primary results of the pivotal CHRONOS-1 study, which looked at copanlisib in patients with relapsed or refractory indolent B-cell lymphoma, during the AACR Annual Meeting.